# A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)

> **NCT04439071** · PHASE2,PHASE3 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 189 (actual)

## Conditions studied

- Pneumonia
- COVID-19
- Coronavirus

## Interventions

- **DRUG:** PTC299
- **OTHER:** SOC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04439071
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-09
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 189 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439071, "A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04439071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*